U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C15H16N4O2
Molecular Weight 284.3131
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NICARAVEN

SMILES

CC(CNC(=O)C1=CC=CN=C1)NC(=O)C2=CC=CN=C2

InChI

InChIKey=KTXBOOWDLPUROC-UHFFFAOYSA-N
InChI=1S/C15H16N4O2/c1-11(19-15(21)13-5-3-7-17-10-13)8-18-14(20)12-4-2-6-16-9-12/h2-7,9-11H,8H2,1H3,(H,18,20)(H,19,21)

HIDE SMILES / InChI

Molecular Formula C15H16N4O2
Molecular Weight 284.3131
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Nicaraven is a hydroxyl radical scavenger with antivasospastic and neuroprotective effects. Chugai (the Japanese subsidiary of Roche) is developing nicaraven (Antevas), a water-soluble antioxidant, for the potential treatment of disorders caused by acute cerebrovascular diseases. A registration application was filed in April 1995, and in April 2002, nicaraven was still awaiting registration in Japan. By August 2002, Chugai had filed an NDA in Japan for the additional indication of subarachnoidal bleeding.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.5 mM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Effects of a hydroxyl radical scavenger on delayed ischemic neurological deficits following aneurysmal subarachnoid hemorrhage: results of a multicenter, placebo-controlled double-blind trial.
1996 May
The potential benefits of nicaraven to protect against radiation-induced injury in hematopoietic stem/progenitor cells with relative low dose exposures.
2014 Sep 26
Nicaraven, a Potential Radioprotective Agent, has Very Limited Effects on the Survival of Cancer Cells and the Growth of Established Tumors.
2017 Feb 22
Patents

Patents

Sample Use Guides

4 g nicaraven infused intravenously for 6-8 hours once a day
Route of Administration: Intravenous
The antiplatelet activities in vitro of nicaraven were examined. The concentrations of nicaraven tested were 3.50 x 10(-5) mol/L, 1.75 x 10(-4) mol/L, 3.50 x 10(-4) mol/L, and 1.75 x 10(-3) mol/L, respectively. The maximum aggregation rate induced by adenosine diphosphate (ADP) was significantly inhibited by nicaraven at concentration ranges of 3.50 x 10(-4) mol/L or higher in the healthy volunteer platelets. The maximum aggregation rate induced by collagen was significantly inhibited by 1.75 x 10(-3) mol/L of nicaraven. Using platelets from patients with cerebral thrombosis, the maximum aggregation rate induced by ADP was significantly inhibited by 1.75 x 10(-3) mol/L of nicaraven. Furthermore, the maximum aggregation rate induced by collagen were significantly reduced by 1.75 x 10(-3) mol/L of nicaraven.
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:58:22 GMT 2023
Edited
by admin
on Sat Dec 16 17:58:22 GMT 2023
Record UNII
UD8PEV6JBD
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NICARAVEN
INN   MART.   MI  
INN  
Official Name English
NICARAVEN [MI]
Common Name English
nicaraven [INN]
Common Name English
AVS
Common Name English
1,2-BIS(NICOTINAMIDO)PROPANE
Systematic Name English
NICARAVEN [MART.]
Common Name English
NICARAVEN [JAN]
Common Name English
ANTEVAS
Common Name English
(±)-N,N'-PROPYLENEBIS(NICOTINAMIDE)
Systematic Name English
3-PYRIDINECARBOXAMIDE, N,N'-(1-METHYL-1,2-ETHANEDIYL)BIS-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C333
Created by admin on Sat Dec 16 17:58:23 GMT 2023 , Edited by admin on Sat Dec 16 17:58:23 GMT 2023
Code System Code Type Description
DRUG BANK
DB06397
Created by admin on Sat Dec 16 17:58:23 GMT 2023 , Edited by admin on Sat Dec 16 17:58:23 GMT 2023
PRIMARY
CAS
79455-30-4
Created by admin on Sat Dec 16 17:58:23 GMT 2023 , Edited by admin on Sat Dec 16 17:58:23 GMT 2023
PRIMARY
INN
6334
Created by admin on Sat Dec 16 17:58:23 GMT 2023 , Edited by admin on Sat Dec 16 17:58:23 GMT 2023
PRIMARY
FDA UNII
UD8PEV6JBD
Created by admin on Sat Dec 16 17:58:23 GMT 2023 , Edited by admin on Sat Dec 16 17:58:23 GMT 2023
PRIMARY
MERCK INDEX
m7848
Created by admin on Sat Dec 16 17:58:23 GMT 2023 , Edited by admin on Sat Dec 16 17:58:23 GMT 2023
PRIMARY Merck Index
NCI_THESAURUS
C76580
Created by admin on Sat Dec 16 17:58:23 GMT 2023 , Edited by admin on Sat Dec 16 17:58:23 GMT 2023
PRIMARY
SMS_ID
100000084186
Created by admin on Sat Dec 16 17:58:23 GMT 2023 , Edited by admin on Sat Dec 16 17:58:23 GMT 2023
PRIMARY
ChEMBL
CHEMBL1705525
Created by admin on Sat Dec 16 17:58:23 GMT 2023 , Edited by admin on Sat Dec 16 17:58:23 GMT 2023
PRIMARY
EPA CompTox
DTXSID6046189
Created by admin on Sat Dec 16 17:58:23 GMT 2023 , Edited by admin on Sat Dec 16 17:58:23 GMT 2023
PRIMARY
PUBCHEM
71234
Created by admin on Sat Dec 16 17:58:23 GMT 2023 , Edited by admin on Sat Dec 16 17:58:23 GMT 2023
PRIMARY
MESH
C042625
Created by admin on Sat Dec 16 17:58:23 GMT 2023 , Edited by admin on Sat Dec 16 17:58:23 GMT 2023
PRIMARY
EVMPD
SUB09224MIG
Created by admin on Sat Dec 16 17:58:23 GMT 2023 , Edited by admin on Sat Dec 16 17:58:23 GMT 2023
PRIMARY
CAS
160888-15-3
Created by admin on Sat Dec 16 17:58:23 GMT 2023 , Edited by admin on Sat Dec 16 17:58:23 GMT 2023
SUPERSEDED
Related Record Type Details
SALT/SOLVATE -> PARENT
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
Related Record Type Details
ACTIVE MOIETY